AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (519.7 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

Cancer stem cells and HER2 positive breast cancer: The story so far

Deep Shaha, Clodia Osipob,( )
Department of Molecular Pharmacology and Therapeutics, Oncology Research Institute, Loyola University Chicago, Maywood, IL 60153, USA
Department of Microbiology and Immunology, Oncology Research Institute, Loyola University Chicago, Maywood, IL 60153, USA

Peer review under responsibility of Chongqing Medical University.

Show Author Information

Abstract

Human Epidermal Growth Factor Receptor type 2 (HER2) gene amplification and/or protein overexpression is observed in patients suffering from HER2+ breast cancer. This subtype of breast cancer has improved prognosis due to availability of anti-HER2 therapy. However, drug resistance and tumor recurrence still remains a major concern. Cancer Stem Cells (CSCs) are believed to constitute the subset of cell population that is resistant to drug treatment and possesses characteristics of stem cells. CSCs enable the tumors to thrive despite major insults. This review provides a comprehensive idea about the concept of CSCs in context of HER2+ breast cancer by providing the description of the markers that are used for the identification of CSCs and by elucidating the signaling pathways that are associated with HER2+ breast CSCs. Furthermore, the review also describes the interaction of HER2 with those signaling pathways and the future of targeting CSCs in HER2+ breast cancer.

Keywords

Drug resistanceBreast cancerSignaling pathwaysCancer stem cells (CSCs)Human epidermal growth factor receptor type 2 (HER2)

References

1
Breast Cancer Facts – National Breast Cancer Foundation. Website http://www.nationalbreastcancer.org/breast-cancer-facts. (accessed 20.03.15).
2
Breast Cancer Statistics - Susan G Komen®. Website http://ww5.komen.org/BreastCancer/Statistics.html. Updated February 3, 2016. (accessed 04.02.16).
3
Goldberg K. ASCO Issues Two New Guidelines on Treating Patients with Advanced, HER2-positive Breast Cancer. American Society of Clinical Oncology Website http://www.asco.org/press-center/asco-issues-two-new-guidelines-treating-patients-advanced-her2-positive-breast-cancer. Updated May 5, 2014. (accessed 20.03.15).
4

Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol. 2010;23(Suppl 2):S60-S64.
Crossref Google Scholar
5

Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 2012;12:553-563.
Crossref Google Scholar
6

Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-137.
Crossref Google Scholar
7

Mayer EL. Targeting breast cancer with CDK inhibitors. Curr Oncol Rep. 2015;17:443.
Crossref Google Scholar
8

Lavaud P, Andre F. Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med. 2014;12:132.
Crossref Google Scholar
9

Muller P, Kreuzaler M, Khan T, et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med. 2015;7:315ra188.
Crossref Google Scholar
10

Abravanel DL, Belka GK, Pan TC, et al. Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy. J Clin Invest. 2015;125:2484-2496.
Crossref Google Scholar
11

Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog. 2012;17:1-16.
Crossref Google Scholar
12

Mehta K, Osipo C. Trastuzumab resistance: role for Notch signaling. ScientificWorldJournal. 2009;9:1438-1448.
Crossref Google Scholar
13

Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320-368.
Crossref Google Scholar
14

D'Amato V, Raimondo L, Formisano L, et al. Mechanisms of lapatinib resistance in HER2-driven breast cancer. Cancer Treat Rev. December 2015;41:877-883.
Crossref Google Scholar
15

Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010;120:41-50.
Crossref Google Scholar
16

Jordan CT. Cancer stem cells: controversial or just misunderstood? Cell Stem Cell. 2009;4:203-205.
Crossref Google Scholar
17

Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704-715.
Crossref Google Scholar
18

Tsuji T, Ibaragi S, Shima K, et al. Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res. 2008;68:10377-10386.
Crossref Google Scholar
19

Owens TW, Naylor MJ. Breast cancer stem cells. Front Physiol. 2013;4:225.
Crossref Google Scholar
20

Liu S, Cong Y, Wang D, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep. 2014;2:78-91.
Crossref Google Scholar
21

Ithimakin S, Day KC, Malik F, et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res. 2013;73:1635-1646.
Crossref Google Scholar
22

Duru N, Fan M, Candas D, et al. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res. 2012;18:6634-6647.
Crossref Google Scholar
23

Rahmatpanah F, Jia Z, Chen X, Jones FE, McClelland M, Mercola D. Expression of HER2 in breast cancer promotes a massive reorganization of gene activity and suggests a role for epigenetic regulation. J Data Min Genomics Proteomics.2012; 3.
Google Scholar
24

Liu JC, Voisin V, Bader GD, et al. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERalpha- breast cancer. Proc Natl Acad Sci U S A. 2012;109:5832-5837.
Crossref Google Scholar
25

Magnifico A, Albano L, Campaner S, et al. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res. 2009;15:2010-2021.
Crossref Google Scholar
26

Diessner J, Bruttel V, Stein RG, et al. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death Dis. 2014;5:e1149.
Crossref Google Scholar
27

Oak PS, Kopp F, Thakur C, et al. Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells. Int J Cancer. 2012;131:2808-2819.
Crossref Google Scholar
28

Hori K, Sen A, Artavanis-Tsakonas S. Notch signaling at a glance. J Cell Sci. 2013;126(Pt 10):2135-2140.
Crossref Google Scholar
29

Osipo C, Patel P, Rizzo P, et al. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene. 2008;27:5019-5032.
Crossref Google Scholar
30

Pandya K, Meeke K, Clementz AG, et al. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Cancer. 2011;105:796-806.
Crossref Google Scholar
31

Harrison H, Farnie G, Howell SJ, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010;70:709-718.
Crossref Google Scholar
32

Rao TP, Kuhl M. An updated overview on Wnt signaling pathways: a prelude for more. Circ Res. 2010;106:1798-1806.
Crossref Google Scholar
33

Yamaguchi H, Chang SS, Hsu JL, Hung MC. Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene. 2014;33:1073-1081.
Crossref Google Scholar
34

Wu Y, Ginther C, Kim J, et al. Expression of Wnt3 activates Wnt/beta-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012;10:1597-1606.
Crossref Google Scholar
35

Hallett RM, Kondratyev MK, Giacomelli AO, et al. Small molecule antagonists of the Wnt/beta-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer. PLoS One. 2012;7:e33976.
Crossref Google Scholar
36

Flemban A, Qualtrough D. The potential role of hedgehog signaling in the Luminal/Basal phenotype of breast Epithelia and in breast Cancer invasion and metastasis. Cancers. 2015;7:1863-1884.
Crossref Google Scholar
37

Kasper M, Jaks V, Fiaschi M, Toftgard R. Hedgehog signalling in breast cancer. Carcinogenesis. 2009;30:903-911.
Crossref Google Scholar
38

Kebenko M, Drenckhan A, Gros SJ, et al. ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts. Cell Signal. 2015;27:373-381.
Crossref Google Scholar
39

Im S, Choi HJ, Yoo C, et al. Hedgehog related protein expression in breast cancer: gli-2 is associated with poor overall survival. Korean J Pathol. 2013;47:116-123.
Crossref Google Scholar
40

Xia Y, Shen S, Verma IM. NF-kappaB, an active player in human cancers. Cancer Immunol Res. 2014;2:823-830.
Crossref Google Scholar
41

Merkhofer EC, Cogswell P, Baldwin AS. Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha. Oncogene. 2010;29:1238-1248.
Crossref Google Scholar
42

Cao Y, Luo JL, Karin M. IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci U S A. 2007;104:15852-15857.
Crossref Google Scholar
43

Jiang Z, Liu JC, Chung PE, Egan SE, Zacksenhaus E. Targeting HER2(+) breast cancer: the TBK1/IKKepsilon axis. Oncoscience. 2014;1:180-182.
Crossref Google Scholar
44

Korkaya H, Kim GI, Davis A, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell. 2012;47:570-584.
Crossref Google Scholar
45

Singh JK, Simoes BM, Howell SJ, Farnie G, Clarke RB. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 2013;15:210.
Crossref Google Scholar
46

Singh JK, Farnie G, Bundred NJ, et al. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res. 2013;19:643-656.
Crossref Google Scholar
47

Quintas-Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res. 2013;19:1933-1940.
Crossref Google Scholar
48

Chung SS, Giehl N, Wu Y, Vadgama JV. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol. 2014;44:403-411.
Crossref Google Scholar
49

Sheen YY, Kim MJ, Park SA, Park SY, Nam JS. Targeting the transforming growth factor-beta signaling in Cancer therapy. Biomol Ther. 2013;21:323-331.
Crossref Google Scholar
50

Moses H, Barcellos-Hoff MH. TGF-beta biology in mammary development and breast cancer. Cold Spring Harb Perspect Biol. 2011;3:a003277.
Crossref Google Scholar
51

Wang SE. The functional crosstalk between HER2 tyrosine kinase and TGF-beta signaling in breast cancer malignancy. J Signal Transduct. 2011;2011:804236.
Crossref Google Scholar
52

Lo PK, Kanojia D, Liu X, et al. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFbeta signaling. Oncogene. 2012;31:2614-2626.
Crossref Google Scholar
53

Lauring J, Park BH, Wolff AC. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw. 2013;11:670-678.
Crossref Google Scholar
54

Chakrabarty A, Bhola NE, Sutton C, et al. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res. 2013;73:1190-1200.
Crossref Google Scholar
55

Hanker AB, Pfefferle AD, Balko JM, et al. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci U. S. A. 2013;110:14372-14377.
Crossref Google Scholar
56

Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell. 2015;16:225-238.
Crossref Google Scholar
57

Gao D, Vahdat LT, Wong S, Chang JC, Mittal V. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res. 2012;72:4883-4889.
Crossref Google Scholar
58

Wang SE, Yu Y, Criswell TL, et al. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators. Oncogene. 2010;29:3335-3348.
Crossref Google Scholar
59

Mao Y, Zhang Y, Qu Q, et al. Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells. Mol Biosyst. 2015;11:1029-1040.
Crossref Google Scholar
60

Korkaya H, Wicha MS. HER2 and breast cancer stem cells: more than meets the eye. Cancer Res. 2013;73:3489-3493.
Crossref Google Scholar
61

Banys M, Hartkopf AD, Krawczyk N, et al. Dormancy in breast cancer. Breast Cancer (Dove Med Press). 2012;4:183-191.
Crossref Google Scholar
Genes & Diseases
Volume 3 Issue 2,
June 2016
Pages 114-123
DOI: 10.1016/j.gendis.2016.02.002
Cite this article:
Shah D, Osipo C. Cancer stem cells and HER2 positive breast cancer: The story so far. Genes & Diseases, 2016, 3(2): 114-123. https://doi.org/10.1016/j.gendis.2016.02.002

218

Views

4

Downloads

39

Crossref

N/A

Web of Science

43

Scopus

0

CSCD

Altmetrics
Received: 27 October 2015
Accepted: 11 February 2016
Published: 21 February 2016
© 2016, Chongqing Medical University.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return